STUDY OF THE INVOLVEMENT OF AMPA RECEPTORS IN THE ANTIHYPOXIC EFFECT OF THE NEUROPEPTIDE CYCLO-PROLYL-GLYCINE

DOI: https://doi.org/10.29296/25877313-2020-09-06
Issue: 
9
Year: 
2020

K.N. Koliasnikova Ph.D. (Biol.), FSBI «Zakusov Institute of Pharmacology» (Moscow) A.G. Alyaeva Junior Research Scientist, FSBI «Zakusov Institute of Pharmacology» (Moscow) O.N. Vorontsova Ph.D. (Biol.), FSBI «Zakusov Institute of Pharmacology» (Moscow) T.A. Gudasheva Dr.Sc. (Biol.), Professor, Corr. Member RAS, FSBI «Zakusov Institute of Pharmacology» (Moscow) E-mail: tata-sosnovka@mail.ru

Relevance. Cyclo-prolyl-glycine (CPG) was designed and synthesized at the Zakusov Research Institute of Pharmacology as a topological analogue of the nootropic drug piracetam and was later discovered as an endogenous compound in the rat brain. It had a spectrum of pharmacological characteris-tics of piracetam, including antihypoxic activity. However, there is still no evident data of the mechanism of action of this neuropeptide. Therefore, clarification of the mechanism of action of CPG is relevant. Objective. Purpose of the study is to reveal the involvement of AMPA receptors in the antihypoxic effect of the neuropeptide CPG. Material and methods. The method of inhibitory pharmacological analysis using a selective antagonist of AMPA receptors of the compound DNQX was used. Antihypoxic activity was evaluated on a normobaric hypoxia model with hypercapnia in BALB/c mice. Results. The antihypoxic effect of CPG at the dose of 1 mg/kg intraperitoneally was completely removed by a specific blocker of AMPA receptors, compound DNQX, at the dose of 10 mg/kg intraperitoneally. Conclusions. For the first time it was shown that AMPA receptors are involved in the antihypoxic effect of the neuropeptide cyclo-prolyl-glycine.

Keywords: 
cyclo-prolyl-glycine
antihypoxic activity
AMPA
DNQX

References: 
  1. Gudasheva T.A., Ostrovskaya R.U., Maksimova F.V., Chuppin A.V., Trofimov S.S., Lezina V.P., Voronina T.A., Skoldinov A.P. Topologicheskie analogi piracetama na osnove prolina i ih nootropnaya aktivnost’. Himiko-farmacevticheskij zhurnal. 1989; 23(3): 276-81.
  2. Gudasheva T.A., Boyko S.S., Akparov V.Kh., Ostrovskaya R.U., Skoldinov A.P., Rozantsev G.G., Voronina T.A., Zherdev V.P., Seredenin S.B. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Letters. 1996; 391: 149-152.
  3. Gudasheva T.A., Konstantinopol’skij M.A., Ostrovskaya R.U., Seredenin S.B. Anksioliticheskaya aktivnost’ endogennogo nootropa ciklo-prolilglicina v teste pripodnyatogo krestoobraznogo labirinta stereoselektivna. Byul. eksper. biol. med. 2001; 131(5): 547-550.
  4. Guan J., Gluckman P., Yang P., et al. Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1. Scientific reports. 2014. 4: 4388.
  5. Kolyasnikova K.N., Gudasheva T.A., Nazarova G.A. i dr. Skhodstvo ciklo-prolilglicina s piracetamom po antigipoksicheskomu i nejroprotektornomu effektam. Eksper. klin. farmakol. 2012; 75(9): 3-6.
  6. Guan J., Singh-Mallah G., Liu K., et al. The role for cyclic Glycine-Proline, a biological regulator of insulin-like growth factor-1 in pregnancy-related obesity and weight changes. J. Biol. Regul. Homeost. Agents. 2018;32(3):465-478.
  7. Gudasheva T.A., Grigor’ev V.V., Kolyasnikova K.N., Zamojskij V.L., Seredenin S.B. Nejropeptid ciklo-prolilglicin yavlyaetsya endogennym polozhitel’nym modulyatorom AMRA-receptorov. Doklady Akademii nauk. 2016; 471(1):106-108.
  8. Gudasheva T.A., Kolyasnikova K.N., Antipova T.A., Seredenin S.B. Nejropeptid cikloprolilglicin uvelichivaet soderzhanie mozgovogo nejrotroficheskogo faktora v nejronal’nyh kletkah. Doklady Akademii nauk. 2016; 469(4): 492–495.
  9. Aguado-Llera D., Canelles S., Fernandez-Mendivil C., et al. Improvement in inflammation is associated with the pro tective effect of Gly-Pro-Glu and cycloprolylglycine against Aβ-induced depletion of the hippocampal somatostatinergic system. Neuropharmacology. 2019. 151. 112–126.
  10. Rial D., Takahashi R.N., Morato G.S. Aniracetam and DNQX affect the acquisition of rapid tolerance to ethanol in mice. Pharmacol Biochem Behav. 2009; 92(1): 32-38. DOI: 10.1016/j.pbb.2008.10.006.
  11. Voronina, T.A. Ostrovskaya R.U., Garibova T.L. Metodicheskie rekomendacii po doklinicheskomu izucheniyu lekarstvennyh sredstv s nootropnym tipom dejstviya. V kn. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Pod obshch. red. A.N. Mironova. Chast’ 1, M.: Grif i K, 2012; s.276-296.